Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CGTX
#4076
Cognition Therapeutics, Inc. Common Stock
1.1
0
USD
+0.92%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.92%
Monthly Change
-0.90%
6 month change
-39.23%
Year Change
+182.05%
Previous Close
1.0
9
Open
1.0
9
Bid
Ask
Low
1.0
8
High
1.1
0
Volume
45
Markets
US Stock Market
Healthcare
CGTX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Cash from operating activities
-8.38 M
-9.88 M
-5.62 M
-5.65 M
-3.44 M
-24.59 M
Cash from investing activities
-1 000
—
—
—
—
—
Cash from financing activities
11.38 M
1.3 M
752 K
33.92 M
605 K
36.57 M
Free cash flow
-8.38 M
-9.88 M
-5.62 M
-5.65 M
-3.44 M
-24.59 M
News
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition presents data on dementia drug zervimesine at conference
Cognition Therapeutics shifts focus to DLB psychosis treatment
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug
Cognition’s DLB drug shows positive results in phase 2 trial
Cognition Therapeutics completes enrollment in expanded access program
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)
Cognition Therapeutics completes enrollment in Alzheimer’s drug trial
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition’s Alzheimer’s drug trial reaches 75% enrollment milestone